RecruitingAtopic Dermatitis (AD)

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Eligible age

18–75 yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Sponsor: Bluefin Biomedicine, Inc.

You may qualify if…

✓ Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
✓ Have moderate to severe disease not adequately controlled by topical treatments.
✓ Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.